Updates are available Correction dated 2022-07-19
Click to view Correction: https://doi.org/10.1186/s13073-022-01086-y
-
Authors
Bartlett, Thomas E.
Evans, Iona
Jones, Allison
Barrett, James E.
Haran, Shaun
Reisel, Daniel
Papaikonomou, Kiriaki
Jones, Louise
Herzog, Chiara https://orcid.org/0000-0002-1572-498X
Pashayan, Nora
Simões, Bruno M.
Clarke, Robert B.
Evans, D. Gareth
Ghezelayagh, Talayeh S.
Ponandai-Srinivasan, Sakthivignesh
Boggavarapu, Nageswara R.
Lalitkumar, Parameswaran G.
Howell, Sacha J.
Risques, Rosa Ana
Rådestad, Angelique Flöter
Dubeau, Louis
Gemzell-Danielsson, Kristina
Widschwendter, Martin https://orcid.org/0000-0002-7778-8380
-
Funding
Funding for this research was provided by:
H2020 European Research Council (742432)
The Eve Appeal
Vetenskapsrådet (2017-00932, 2012-02961)
Cancerfonden (CAN 2016/696)
Radiumhemmets Forskningsfonder (154143, 184033)
Manchester Biomedical Research Centre (IS-BRC-1215-20007)
Medical Research Council (MR/P014070/1)
- License Information
-
More Information
Article History
Received: 11 March 2021
Accepted: 17 May 2022
First Online: 15 June 2022
Change Date: 19 July 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13073-022-01086-y
Declarations
:
: Clinical Trials 1–2 <i>(‘Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control – a randomized controlled trial’</i> and <i>‘The effect of a progesterone receptor modulator on breast tissue in women with BRCA1 and 2 mutations’</i>) were approved by the regional ethical review board at Karolinska Institutet permit 2009/144-31/4 and the regional ethical review board at Karolinska Institutet permit 2012/729 31/1; Clinical Trial 3 (<i>‘A pilot prevention study of the effects of the anti- progestin Ulipristal Acetate (UA) on surrogate markers of breast cancer risk’</i>) was approved by Greater Manchester – South, Research Ethics Committee (REC number 15/NW/0478). Clinical Trials 1–3 conformed to the principles of the Helsinki Declaration. Informed consent was obtained from all participants in Clinical Trials 1–3 to cover all genomic analyses carried out in this study.
: Not applicable.
: RAR owns equity and serves as a scientific consultant to TwinStrand Biosciences Inc. UCLB (UCL's commercialisation company) has filed a patent on some aspects described in the paper – MW is named as inventor on this patent. JEB, CH and MW are shareholders of Sola Diagnostics GmbH, which holds an exclusive licence to the intellectual property described in this patent file. The remaining authors declare that they have no competing interests.
